JP4381810B2 - 選択的エストロゲン受容体βアゴニストとしての置換ベンゾピラン - Google Patents

選択的エストロゲン受容体βアゴニストとしての置換ベンゾピラン Download PDF

Info

Publication number
JP4381810B2
JP4381810B2 JP2003545643A JP2003545643A JP4381810B2 JP 4381810 B2 JP4381810 B2 JP 4381810B2 JP 2003545643 A JP2003545643 A JP 2003545643A JP 2003545643 A JP2003545643 A JP 2003545643A JP 4381810 B2 JP4381810 B2 JP 4381810B2
Authority
JP
Japan
Prior art keywords
mmol
preparation
added
reaction
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003545643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005513027A5 (enExample
JP2005513027A (ja
Inventor
ジェフリー・アラン・ドッジ
ヴェンカテシュ・ゲイリー・クリシュナン
チャールズ・ウィリス・ラガー・ザ・サード
ブレイク・リー・ニューバウアー
ブライアン・ハースト・ノーマン
ランス・アレン・ファイファー
ティモシー・アイボ・リチャードソン
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2005513027A publication Critical patent/JP2005513027A/ja
Publication of JP2005513027A5 publication Critical patent/JP2005513027A5/ja
Application granted granted Critical
Publication of JP4381810B2 publication Critical patent/JP4381810B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
JP2003545643A 2001-11-19 2002-11-07 選択的エストロゲン受容体βアゴニストとしての置換ベンゾピラン Expired - Fee Related JP4381810B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33276601P 2001-11-19 2001-11-19
US36362202P 2002-03-11 2002-03-11
PCT/US2002/033622 WO2003044006A1 (en) 2001-11-19 2002-11-07 Substituted benzopyrans as selective estrogen receptor-beta agonists

Publications (3)

Publication Number Publication Date
JP2005513027A JP2005513027A (ja) 2005-05-12
JP2005513027A5 JP2005513027A5 (enExample) 2006-01-05
JP4381810B2 true JP4381810B2 (ja) 2009-12-09

Family

ID=26988373

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003545643A Expired - Fee Related JP4381810B2 (ja) 2001-11-19 2002-11-07 選択的エストロゲン受容体βアゴニストとしての置換ベンゾピラン

Country Status (23)

Country Link
US (1) US7217734B2 (enExample)
EP (1) EP1448544B1 (enExample)
JP (1) JP4381810B2 (enExample)
KR (1) KR100950616B1 (enExample)
CN (1) CN1312147C (enExample)
AT (1) ATE362471T1 (enExample)
AU (1) AU2002359283B2 (enExample)
CA (1) CA2467013C (enExample)
CY (1) CY1106726T1 (enExample)
DE (1) DE60220179T2 (enExample)
DK (1) DK1448544T3 (enExample)
EA (1) EA007382B1 (enExample)
EC (1) ECSP045113A (enExample)
ES (1) ES2286322T3 (enExample)
HR (1) HRP20040439A2 (enExample)
HU (1) HU229351B1 (enExample)
IL (3) IL161325A0 (enExample)
MX (1) MXPA04004703A (enExample)
NO (1) NO328563B1 (enExample)
NZ (1) NZ531850A (enExample)
PL (1) PL205733B1 (enExample)
PT (1) PT1448544E (enExample)
WO (1) WO2003044006A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279499B2 (en) 2003-04-21 2007-10-09 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
EP1626974B1 (en) * 2003-04-21 2008-08-27 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
JP2008512458A (ja) 2004-09-07 2008-04-24 ワイス 6H−[1]ベンゾピラノ[4,3−b]キノリン及びエストロゲン様物質としてのそれらの使用
ATE504582T1 (de) * 2004-10-18 2011-04-15 Lilly Co Eli Substituierte benzopyrane als selektive östrogenrezeptor-beta-agonisten
US20060166933A1 (en) * 2004-11-18 2006-07-27 Jain Nareshkumar F Novel 2H-chromene derivatives as selective estrogen receptor modulators
US8093302B2 (en) 2005-02-15 2012-01-10 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-β agonists
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US8063102B2 (en) 2009-03-13 2011-11-22 N.V. Organon Tetrahydronaphthalen-2-ol derivatives
TW201043595A (en) 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
CN105960236A (zh) 2013-12-05 2016-09-21 卡罗医药股份公司 用于治疗间皮瘤的雌激素受体β激动剂
JP6978420B2 (ja) 2015-09-17 2021-12-08 オハイオ・ステート・イノヴェーション・ファウンデーション カルボラン化合物及びその使用方法
WO2021183760A1 (en) * 2020-03-11 2021-09-16 Ohio State Innovation Foundation Methods of modulating t-cell activation using estrogen receptor beta (erβ) agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901926A (en) * 1973-04-02 1975-08-26 Abbott Lab Alkylphenyl benzopyrans
EP0935000A3 (en) 1995-09-08 1999-09-08 Karo Bio Ab Orphan receptor
AU8102398A (en) * 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
JP2003521468A (ja) 1999-03-17 2003-07-15 シグナル ファーマシューティカルズ, インコーポレイテッド エストロゲンレセプタを変調させるための化合物及び方法
TR200102992T2 (tr) 1999-04-16 2004-12-21 Astrazeneca Ab ß östrojen reseptörü ligandları.
CA2396059A1 (en) 1999-12-30 2001-07-12 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US7214706B2 (en) * 2000-03-01 2007-05-08 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
ES2293986T3 (es) 2000-03-27 2008-04-01 N.V. Organon Compuestos no esteroides tetraciclicos para tratamientos relacionados con el estrogeno.
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6630508B1 (en) * 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists

Also Published As

Publication number Publication date
PL205733B1 (pl) 2010-05-31
NO20042583L (no) 2004-06-18
NO328563B1 (no) 2010-03-22
KR20040063963A (ko) 2004-07-15
US7217734B2 (en) 2007-05-15
HK1068349A1 (en) 2005-04-29
AU2002359283B2 (en) 2007-06-21
MXPA04004703A (es) 2004-08-19
PL374510A1 (en) 2005-10-31
DE60220179D1 (de) 2007-06-28
ES2286322T3 (es) 2007-12-01
IL161325A (en) 2008-07-08
IL161325A0 (en) 2004-09-27
HRP20040439A2 (en) 2005-04-30
CN1589268A (zh) 2005-03-02
US20040249167A1 (en) 2004-12-09
EA200400695A1 (ru) 2004-12-30
CY1106726T1 (el) 2012-05-23
IL185867A0 (en) 2008-01-06
KR100950616B1 (ko) 2010-04-01
EP1448544B1 (en) 2007-05-16
AU2002359283A1 (en) 2003-06-10
JP2005513027A (ja) 2005-05-12
NZ531850A (en) 2007-01-26
PT1448544E (pt) 2007-08-10
CN1312147C (zh) 2007-04-25
HUP0402628A2 (hu) 2005-04-28
HU229351B1 (en) 2013-11-28
EA007382B1 (ru) 2006-10-27
ECSP045113A (es) 2004-07-23
EP1448544A1 (en) 2004-08-25
CA2467013C (en) 2010-08-10
ATE362471T1 (de) 2007-06-15
CA2467013A1 (en) 2003-05-30
IL185867A (en) 2009-09-22
DE60220179T2 (de) 2008-02-07
WO2003044006A1 (en) 2003-05-30
DK1448544T3 (da) 2007-10-08
AU2002359283B8 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
IL185867A (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
JP3348859B2 (ja) プロテインキナーゼcインヒビター
EP1618102B1 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
US20040236116A1 (en) Novel bicyclic and tricyclic cannabinoids
EP1626974B1 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
US6630508B1 (en) Substituted benzopyrans as selective estrogen receptor β agonists
US7354951B2 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
US8637685B2 (en) Schweinfurthin analogues
JP2008540368A (ja) 5−ht2リガンドとしての四環式アザピラジノインドリン
EP1790644A1 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
HK1068349B (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
WO2003074044A1 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
ZA200403733B (en) Substituted benzopyrans as selective estrogen receptorbeta agonists.
UA77986C2 (en) Substituted benzopyran derivatives as selective estrogen beta-receptor agonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050901

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050901

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20080911

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081209

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20081210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090304

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090818

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090916

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20121002

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20131002

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees